This inventor holds 1 USPTO granted patent and 8 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Mike Ufer: Innovator in Modified Release Formulations
Introduction
Mike Ufer is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of drug formulations. His work focuses on improving treatment options for patients suffering from Parkinson's disease.
Latest Patents
Mike Ufer holds a patent for a modified release formulation for (-)-(3AR,4S,7AR)-4-hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester. This patent describes drug products in the form of modified release formulations comprising the drug substance (−)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056). These drug products are particularly useful in treating patients with Parkinson's disease who exhibit L-dopa induced dyskinesia.
Career Highlights
Mike Ufer is currently employed at Novartis AG, a leading global healthcare company. His role involves research and development of innovative drug formulations that enhance patient care and treatment efficacy. His expertise in modified release formulations has positioned him as a key player in the pharmaceutical industry.
Collaborations
Throughout his career, Mike has collaborated with several professionals, including Karsten Putzbach and Dirk Spickermann. These collaborations have contributed to the advancement of his research and the successful development of new drug products.
Conclusion
Mike Ufer's contributions to the field of pharmaceuticals, particularly through his patent for modified release formulations, highlight his commitment to improving treatment options for patients with Parkinson's disease. His work at Novartis AG and collaborations with other professionals further emphasize his impact on the industry.